SLP signs lease agreement for 19,300 sqm with Meds Apotek in Eskilstuna

SLP has signed a 5.5‑year lease with Meds Apotek AB for approximately 19,300 sqm at the Litografen 8 logistics property in Eskilstuna (the building totals ~27,000 sqm); Meds will occupy the space from 1 August 2026 after current tenant Tamro vacates early. The agreement secures a growing e‑commerce pharmaceutical tenant, reduces prospective vacancy risk, and leaves scope for value‑adding projects (solar installation and ~10,000 sqm of new production), supporting SLP’s asset‑development strategy across its ~1.5m sqm portfolio and improving near‑term cashflow visibility.

Analysis

Market structure: This lease crystallizes demand for specialist logistics (pharma e-commerce) in secondary Swedish hubs — winner: SLP (Nasdaq Stockholm: SLP B) and Meds Apotek; loser: owners of higher-vacancy, non-specialist logistics and some short-term third‑party distributors. A 19.3k sqm, 5.5‑year deal in a 27k sqm asset (≈71% of building) plus option to build +10k sqm signals durable leasing velocity and tenant-led capex potential, tightening effective supply for specialized pharma logistics within a 100–200 km radius.

Risk assessment: Near-term (days–months) impact is limited because the lease starts 1 Aug 2026; main risks are execution (construction/permits for the +10k sqm), single-tenant concentration, and tenant credit (Meds). Tail risks: regulatory change in Swedish pharma distribution or Meds insolvency (low-prob but high-impact). Over 12–36 months, successful development + solar could lift portfolio NOI by a low‑teens percent on that asset, but rising yields or construction delays could erase gains.

Trade implications: Prefer overweight logistics REITs and underweight office/commodity-sensitive property names. Specific vehicles: SLP B (direct beneficiary), larger liquid longs for portfolio exposure: SEGRO (SGRO.L) and Prologis (PLD). Options: use 9–12 month call spreads on PLD/SGRO to express upside with limited risk. Target re-rating window: 6–18 months as market prices reduced vacancy and development optionality.

Contrarian angles: Consensus may underprice optionality from a 10k sqm extension plus solar (energy cost savings and ESG premium), which could add ~3–7% NAV if executed; conversely markets may be complacent about timing — valuation benefit likely realized only after permits/leases, not at announcement. Historical parallel: e‑commerce logistics re-ratings (2016–19) required visible cashflow; absence of near-term cashflow means buy selective and size positions to event risk.

Key Decisions for Investors

• Establish a 2–3% long position in SLP B (Nasdaq Stockholm: SLP B) within 30 days, target +20% upside in 12 months if visible permitting/lease milestones achieved, stop-loss at -10% to limit downside from execution risk.
• Overweight large-cap logistics REITs: initiate 1–2% longs in SEGRO (SGRO.L) and Prologis (PLD) as portfolio hedges to idiosyncratic Swedish execution risk; add if either stock falls >8% on macro weakness (buy-the-dip).
• Pair trade: long SGRO.L (1.5%) + short Derwent London (DLN.L) or another UK office landlord (1%) to express rotation from offices to logistics; rebalance after 6 months or if office yields compress by <50 bps.
• Options: buy 9–12 month call spreads on PLD (e.g., buy 12-month 5–15% OTM call, sell 25% OTM) sized to 0.5–1% notional to cap premium while capturing sector upside if yields compress.
• Monitor Swedish pharma distribution regulation and SLP permit filings daily for 90 days; if a favourable regulatory/permit milestone is announced, add 1–2% to SLP B position within 5 trading days.